Compare PAYP & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | ALKS |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | Japan | Ireland |
| Employees | 4567 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 8.7B |
| IPO Year | 2026 | 2012 |
| Metric | PAYP | ALKS |
|---|---|---|
| Price | $15.50 | $52.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $25.54 | ★ $43.43 |
| AVG Volume (30 Days) | 910.8K | ★ 1.8M |
| Earning Date | 08-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | N/A | $24.26 |
| Revenue Next Year | $20.92 | $4.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.07 | $25.17 |
| 52 Week High | $24.89 | $55.67 |
| Indicator | PAYP | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 59.36 |
| Support Level | $12.07 | $50.49 |
| Resistance Level | $16.45 | $55.67 |
| Average True Range (ATR) | 0.77 | 1.58 |
| MACD | 0.15 | -0.50 |
| Stochastic Oscillator | 51.97 | 40.40 |
PayPay Corp is a FinTech company in Japan that operates a digital finance platform centered on payments, offering a range of payment and financial services to users and merchants. The company has two reportable segments: i) Payment segment: It includes payment settlement services and related services through its PayPay app, and credit payment settlement services such as revolving and installment payment options and cash advances; and ii) Financial service segment: It includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. The majority of revenue is derived from the Payment segment. Geographically, the company's maximum revenue is generated in Japan.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.